Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
US Army
US Department of Justice
AstraZeneca
Dow
Argus Health
Chubb
McKesson

Generated: August 16, 2018

DrugPatentWatch Database Preview

Eli Lilly And Co Company Profile

« Back to Dashboard

Drugs and US Patents for Eli Lilly And Co

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-002 Sep 28, 2017 RX Yes No 7,855,211 ➤ Sign Up Y Y ➤ Sign Up
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-003 Sep 28, 2017 RX Yes No ➤ Sign Up ➤ Sign Up
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-002 Jul 10, 2009 AB RX Yes Yes 8,569,325*PED ➤ Sign Up Y ➤ Sign Up
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-001 Sep 28, 2017 RX Yes No 7,855,211 ➤ Sign Up Y Y ➤ Sign Up
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-002 Sep 28, 2017 RX Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Eli Lilly And Co

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co SARAFEM fluoxetine hydrochloride CAPSULE;ORAL 018936-008 Jul 6, 2000 4,971,998*PED ➤ Sign Up
Eli Lilly And Co PROZAC fluoxetine hydrochloride CAPSULE;ORAL 018936-001 Dec 29, 1987 4,018,895 ➤ Sign Up
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010 8,071,075 ➤ Sign Up
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-001 Jul 10, 2009 5,288,726*PED ➤ Sign Up
Eli Lilly And Co SARAFEM fluoxetine hydrochloride CAPSULE;ORAL 018936-007 Jul 6, 2000 4,971,998*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Solution 30 mg/1.5 mL ➤ Subscribe 2013-01-29
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2013-07-10

Non-Orange Book US Patents for Eli Lilly And Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,906,028 Stable insulin formulations ➤ Sign Up
7,427,275 Medication dispensing apparatus with triple screw threads for mechanical advantage ➤ Sign Up
8,177,449 Spreading implement ➤ Sign Up
8,357,393 Transdermal delivery rate control using amorphous pharmaceutical compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Eli Lilly And Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00698 Netherlands ➤ Sign Up PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918
2107069/02 Switzerland ➤ Sign Up PRODUCT NAME: INSULIN DEGLUDEC + INSULIN ASPART; REGISTRATION NO/DATE: SWISSMEDIC 62648 12.09.2013
0880 Netherlands ➤ Sign Up PRODUCT NAME: SNELWERKENDE INSULIN ASPART; REGISTRATION NO/DATE: EU/1/16/1160 20170109
226 Luxembourg ➤ Sign Up PRODUCT NAME: COMBINATION D'INSULINE DEGLUDEC ET INSULINE ASPARTE SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; FIRST REGISTRATION DATE: 20130121
C/GB00/027 United Kingdom ➤ Sign Up PRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
US Army
Healthtrust
Queensland Health
Dow
Express Scripts
Federal Trade Commission
UBS
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.